Regardless of the sequential decrease in Current Liabilities, during the first quarter 2026, Quick Ratio deteriorated to 0.23 below Champions Oncology Inc 's average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 148 other companies have achieved higher Quick Ratio than Champions Oncology Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 0 to 3793.

Explain Quick Ratio?
How much Cash & cash equivalents CSBR�s has?
What are CSBR�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CSBR Quick Ratio	(Jul 31 2026) Q1	(Apr 30 2026) Q4	(Jan 31 2026) Q3	(Oct 31 2025) Q2	(Jul 31 2025) Q1
Y / Y Current Liabilities Change	176.97 %	187.1 %	-14.44 %	14.34 %	-9.64 %
Y / Y Cash & cash equivalent Change	-57.79 %	-50.21 %	273.76 %	209.22 %	257.02 %
Quick Ratio MRQ	0.23	0.24	1.41	1.03	1.53
CSBR's Total Ranking	# 3793	# 0	# 1386	# 1536	# 1194
Seq. Current Liabilities Change	-5.99 %	187.1 %	-16.18 %	22.42 %	-2.55 %
Seq. Cash & cash equivalent Change	-10.55 %	-50.21 %	14.9 %	-17.52 %	5.52 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 149
Healthcare Sector	# 905
Overall Market	# 3793

Quick Ratio Statistics
High	Average	Low
3.39	1.06	0.07
(Jul 31 2013)		(Jul 31 2017)

Financial Statements
Champions Oncology Inc 's Current Liabilities	$ 19 Millions	Visit CSBR's Balance sheet
Champions Oncology Inc 's Cash & cash equivalent	$ 4 Millions	Visit CSBR's Balance sheet
Source of CSBR's Sales		Visit CSBR's Sales by Geography

Cumulative Champions Oncology Inc 's Quick Ratio

CSBR's Quick Ratio for the trailling 12 Months

CSBR Quick Ratio	(Jul 31 2026) 12 Months	(Apr 30 2026) 12 Months	(Jan 31 2026) 12 Months	(Oct 31 2025) 12 Months	(Jul 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	85.43 %	40.74 %	-6.54 %	-32.48 %	-34.02 %
Y / Y Cash & cash equivalent TTM Growth	8.04 %	85.59 %	252.98 %	69.97 %	20.53 %
Quick Ratio TTM	0.51	0.8	1.33	1.04	0.88
Total Ranking TTM	# 4699	# 0	# 2346	# 3269	# 3183
Seq. Current Liabilities TTM Growth	28.56 %	44.9 %	-3.89 %	3.57 %	-2.42 %
Seq. Cash & cash equivalent TTM Growth	-17.81 %	-12.79 %	22.94 %	22.61 %	41.18 %

Quick ratio ranking by company, industry and sector >> Back to CSBR Financial Strength Comparisons >> Go to Compare CSBR Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q1 2026 to $18.73 millions, cumulative Quick Ratio decreased to 0.51 below the Champions Oncology Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 158 other companies have achieved higher Quick Ratio than Champions Oncology Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2026 from 0 to 4699.

Explain Quick Ratio?
How much Cash & cash equivalents CSBR�s has?
What are CSBR�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 159
Healthcare Sector	# 1003
Within the Market	# 4699

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.01	0.82	0.13
(Jan 31 2014)		(Jan 31 2025)

Companies with similar Quick Ratio in the quarter ending Jul 31 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jul 31 2026 MRQ Cash & cash equivalent	Jul 31 2026 MRQ Current Liabilities
Halozyme Therapeutics Inc	0.61	$ 231.081 Millions	$ 375.965 Millions
Silexion Therapeutics Corp	0.57	$ 2.258 Millions	$ 3.976 Millions
Atlantic Coastal Acquisition Corp Ii	0.52	$ 4.291 Millions	$ 8.225 Millions
Surrozen Inc	0.50	$ 102.039 Millions	$ 203.292 Millions
Pluri Inc	0.40	$ 13.126 Millions	$ 32.719 Millions
Outlook Therapeutics Inc	0.39	$ 11.242 Millions	$ 28.679 Millions
Neurocrine Biosciences Inc	0.37	$ 390.500 Millions	$ 1,046.100 Millions
Curis Inc	0.37	$ 5.100 Millions	$ 13.675 Millions
Creative Medical Technology Holdings Inc	0.36	$ 0.250 Millions	$ 0.699 Millions
Xtant Medical Holdings Inc	0.33	$ 9.870 Millions	$ 29.963 Millions
Champions Oncology Inc	0.23	$ 4.358 Millions	$ 18.729 Millions
ADAPTIN BIO, INC.	0.22	$ 0.670 Millions	$ 3.036 Millions
Armata Pharmaceuticals Inc	0.10	$ 23.952 Millions	$ 250.199 Millions
Agenus Inc	0.08	$ 18.738 Millions	$ 231.820 Millions
Bioatla Inc	0.06	$ 1.544 Millions	$ 23.951 Millions
Viskase Holdings inc	0.06	$ 7.911 Millions	$ 123.630 Millions
Biomx Inc	0.06	$ 0.585 Millions	$ 10.180 Millions
Tevogen Bio Holdings Inc	0.06	$ 1.082 Millions	$ 19.573 Millions

Date modified: 2026-09-13T23:25:19+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.